Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cefo Co. Ltd. currently manages a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The presence of 1 pending office action indicates the current state of the prosecution pipeline. This active matter is assigned to 1 distinct examiner, ensuring that the company's interactions with the USPTO are handled by a single point of review.
The prosecution activity is further localized within 1 distinct art unit. This concentration suggests that the portfolio's technical subject matter falls under a specific regulatory group. CHERNYSHEV, OLGA N is identified as the busiest examiner for the company, currently overseeing 1 pending office action. This individual handles the active examination workload, creating a relationship between the applicant and this specific examiner.
For a practitioner, this data reflects a portfolio with a specific examiner variety. The fact that 1 examiner is responsible for 1 pending action means that the outcome of the company's current prosecution efforts depends on the feedback from CHERNYSHEV, OLGA N. This structure allows for a strategy tailored to the preferences of the assigned examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029239 | COMPOSITION INCLUDING PLGF FOR PREVENTION OR TREATMENT OF NEUROPSYCHOLOGIC DISEASE | CHERNYSHEV, OLGA N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029239 | COMPOSITION INCLUDING PLGF FOR PREVENTION OR TREATMENT OF NEUROPSYCHOLOGIC DISEASE | CHERNYSHEV, OLGA N | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18029239 | COMPOSITION INCLUDING PLGF FOR PREVENTION OR TREATMENT OF NEUROPSYCHOLOGIC DISEASE | CHERNYSHEV, OLGA N | 1675 | §101§102§112 | Non-Final OA | — | Pending | Mar 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCefo Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Olga N Chernyshev has the most, with 1 of Cefo Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
